Butylone

Butylone (β-keto-MBDB, bk-MBDB) is a synthetic entactogen and stimulant of the cathinone and phenethylamine chemical classes, structurally related to MDMA through the addition of a beta-ketone group to the MBDB (N-methyl-1,3-benzodioxolyl-2-butanamine) backbone. It belongs to the MDxx cathinone family alongside methylone, ethylone, and mephedrone, sharing their combination of stimulant and mild entactogenic properties.

Butylone acts as a mixed reuptake inhibitor and releasing agent for serotonin, dopamine, and norepinephrine — the same three monoamine neurotransmitters targeted by MDMA, but with important differences in relative potency at each transporter. Compared to MDMA, butylone has significantly weaker serotonergic activity relative to its dopaminergic effects, meaning the empathogenic, emotionally warm qualities characteristic of MDMA are present but subdued, while stimulant qualities are more prominent. Users describe an experience with moderate euphoria, mild sociability enhancement, increased energy, and some emotional opening — positioned between a stimulant and an entactogen, closer to the stimulant end.

Duration is typically shorter than MDMA — 2–4 hours for primary effects — and the overall intensity is generally considered milder. The comedown is less pronounced than with MDMA in part because the serotonergic depletion is less severe. However, stimulant-related comedown effects (fatigue, mild dysphoria, sleep disruption) are present.

Like other cathinones in the MDxx family, butylone carries entactogen risks — serotonergic toxicity potential in combination, neurotoxic risk with heavy repeated use — in addition to the cathinone-class stimulant risks of cardiovascular stress and compulsive redosing. It is substantially less researched than MDMA, meaning the full safety profile remains incompletely characterized. Harm reduction approaches developed for MDMA provide a reasonable baseline but cannot be assumed to transfer perfectly.